Kamada Ltd.
KMDA Healthcare Drug Manufacturers Specialty & Generic
Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024. In the quarter to June 2026, revenue grew 22.7%, EPS grew 23.1%, free cash flow grew 165.7% and total debt fell 38.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow KMDA
Kamada Ltd. (KMDA) EV/Sales
As of 16 October 2026, Kamada Ltd. (KMDA) trades at a EV/Sales of 2.1×. Over the past ten years it has ranged from 0.7× (December 2017) to 3.7× (June 2017); the current reading is higher than 77% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | 7.36% |
| FY2024 | 1.8× | (4.36%) |
| FY2023 | 1.9× | 23.64% |
| FY2022 | 1.5× | (49.26%) |
| FY2021 | 3.0× | 128.04% |
| FY2020 | 1.3× | (16.43%) |
| FY2019 | 1.6× | 19.80% |
| FY2018 | 1.3× | (3.37%) |
| FY2017 | 1.4× | (42.84%) |
| FY2016 | 2.4× | 36.94% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.9× | (20.13%) |
| Mar 2026 | 2.4× | 24.25% |
| Dec 2025 | 2.0× | (4.64%) |
| Sep 2025 | 2.0× | (12.02%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLRY Tilray Brands, Inc. compare | 0.6× |
| EVO Evotec AG compare | 0.6× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| CGC Canopy Growth Corporation compare | 1.1× |
| KMDA Kamada Ltd. | 2.1× |
| EOLS Evolus, Inc. compare | 2.1× |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 2.8× |
| AQST Aquestive Therapeutics, Inc. compare | 7.9× |
| TKNO Alpha Teknova, Inc. compare | 8.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)